Conclusions
In patients diagnosed with KHE/TA, about 40% will exhibit KMP, confirming established rates. Currently, a lower mortality rate (1.3%) exists likely owing to earlier recognition and treatment implementation with improved medical therapy options. Overall treatment response rates are high at > 70% by 6 months. There was no significant difference in treatment response or durability of disease response comparing sirolimus to vincristine. Our results support individualized treatment decision plans based on disease severity, side effect profile, patient clinical situation, and physician experience. Response criteria and response rates reported here will be useful for guiding future treatment protocols for vascular tumors.